Valuation: Armata Pharmaceuticals, Inc.

Market Cap 151M 131M 124M 113M 211M 14.52B 212M 1.48B 572M 7.36B 568M 556M 23.47B P/E 2026 *
-2.18x
P/E 2027 * -2.82x
Enterprise Value 151M 131M 124M 113M 211M 14.52B 212M 1.48B 572M 7.36B 568M 556M 23.47B EV / Sales 2026 *
35.6x
EV / Sales 2027 * 55x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-7.50%
1 week-24.77%
Current month-26.13%
1 month-10.75%
3 months-40.06%
6 months-58.00%
Current year-35.19%
1 week 3.98
Extreme 3.985
6.64
1 month 3.98
Extreme 3.985
6.64
Current year 3.48
Extreme 3.48
14.98
1 year 2.92
Extreme 2.92
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 10/07/2023
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 08/05/2019
Director/Board Member 66 11/02/2020
Director/Board Member 51 11/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
14/03/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-7.50%-24.77%+41.31%+50.74% 151M
+0.66%+1.83%+47.32%+97.63% 69.69B
+1.32%+0.44%+37.05%+76.08% 61.24B
+2.22%-4.83%-15.32%+360.65% 26.77B
+0.32%+5.47%+27.74%+14.91% 26.12B
-0.89%-2.34%-3.46%-15.24% 24.07B
+0.86%+7.06%+26.06%-14.33% 20.39B
0.00%-10.41%+171.96%+298.75% 15.72B
-0.21%-2.66%+45.07%+160.34% 14.07B
+0.17%-2.74%-9.79%+455.90% 14.03B
Average -0.31%-4.15%+36.80%+148.54% 27.23B
Weighted average by Cap. +0.69%-0.97%+35.02%+125.63%

Financials

2026 *2027 *
Net sales 4.25M 3.68M 3.48M 3.16M 5.92M 408M 5.96M 41.56M 16.06M 207M 15.97M 15.61M 659M 2.75M 2.38M 2.25M 2.04M 3.83M 264M 3.86M 26.89M 10.39M 134M 10.33M 10.1M 427M
Net income -76.6M -66.38M -62.74M -56.96M -107M -7.35B -107M -749M -289M -3.73B -288M -281M -11.88B -72M -62.4M -58.97M -53.54M -100M -6.91B -101M -704M -272M -3.5B -270M -264M -11.17B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
16/09/26 US$4.070 -7.50% 307,471
15/09/26 US$4.400 -20.72% 650,233
14/09/26 US$5.550 +3.16% 4,743,605
11/09/26 US$5.380 +2.87% 43,626
10/09/26 US$5.230 -3.33% 115,382
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.070USD
Average target price
17.50USD
Spread / Average Target
+329.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!